Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers

Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Biological: MEDI-528 0.3 mg/kg; Biological: MEDI-528 1 mg/kg; Biological: MEDI-528 3 mg/kg; Biological: MEDI-528 9 mg/kg

Detailed Description

The primary objective of this Phase I study is to evaluate the safety and tolerability of escalating single IV doses of MEDI-528 administered to healthy adult volunteers.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Louisiana
    • New Orleans, Louisiana, United States
      • MDS Pharma Services

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 49 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females age 18 up to and including 49 years of age at the time of the first dose of study drug
• Weight < 89 kg
• Written informed consent obtained from the volunteer
• Healthy by medical history and physical examination
• Sexually active females, unless surgically sterile or at least one year post-menopausal, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap,abstinence, use of a condom by the sexual partner or sterile sexual partner) for 3 months before the first dose of study drug, and must agree to continue using such precautions through 84 days after their dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions through 84 days after their dose of study drug.
• Use of common over-the-counter medications such as topical corticosteroids, decongestants, antihistamines, analgesics, and antacids is permitted unless, in the opinion of the investigator, it would interfere with either the volunteer's ability to complete the study or interpretation of study results.
• Ability to complete the follow-up period of 84 days
• Willing to forego other forms of experimental treatment during the study period of 84 days

Exclusion Criteria:

• Acute illnesses or evidence of significant active infection, such as fever ≥38.0°C (100.5°F) at the start of the study
• Use of prescription medications, other than contraceptives, in the 28-day period before Study Day 0
• Blood donation in excess of 400 mL within 6 months of the time of entry into the study
• History of use of tobacco products within 3 years of Study Day 0 or history of smoking of >10 pack-years
• History of immunodeficiency or receipt or current use of immunosuppressive drugs including systemic corticosteroids
• History of allergic disease or reactions likely to be exacerbated by any component of the Study Drug (described in the Investigator's Brochure)
• History of substance abuse that, in the opinion of the investigator, may compromise the ability of the study subject to complete the study and follow-up period
• Evidence of any systemic disease on physical examination
• Evidence of infection with hepatitis A, B, or C virus or HIV-1
• Receipt of immunoglobulins or blood products within 60 days of entering the study
• Receipt of any investigational drug therapy within 60 days of the first dose of study drug through Study Day 84 (use of licensed agents for indications not listed in the package insert is permitted)
• Any of the following: CBC: Hgb < 12.0 gm/dL; WBC < 4,000/mm3; platelet count <125,000/mm3 (or laboratory normal values); Na, K, Cl, CO2, AST, ALT, BUN, 4-hour fasting glucose, amylase, lipase, creatinine, troponin > upper limit of normal; other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant.
• Clinically significant abnormality, as determined by the investigator, on 12-lead electrocardiogram at the time of initial screening
• Elective surgery planned during the study period through Study Day 84
• Pregnancy (sexually active females must have a negative serum pregnancy test on the day of the first dose of the study drug, before dosing)
• Nursing mother
• The presence of any acute or chronic organ-specific condition or any concern, which in the opinion of the investigator, may interfere with the conduct or interpretation of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MEDI-528 0.3 mg/kg; MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose	Biological: MEDI-528 0.3 mg/kg; MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
Experimental: MEDI-528 1 mg/kg; MEDI-528 (1 mg/kg) administered as a single, IV dose	Biological: MEDI-528 1 mg/kg; MEDI-528 (1 mg/kg) administered as a single, IV dose
Experimental: MEDI-528 3 mg/kg; MEDI-528 (3 mg/kg) administered as a single, IV dose	Biological: MEDI-528 3 mg/kg; MEDI-528 (3 mg/kg) administered as a single, IV dose
Experimental: MEDI-528 9 mg/kg; MEDI-528 (9 mg/kg) administered as a single, IV dose	Biological: MEDI-528 9 mg/kg; MEDI-528 (9 mg/kg) administered as a single, IV dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events	Number of participants experiencing adverse events (includes both adverse events and serious adverse events)	Days 0 - 84
Incidence of Serious Adverse Events	Number of participants experiencing serious adverse events	Days 0 - 84
Incidence of Abnormal Troponin Levels	Number of participants with troponin levels greater than upper limit of normal (> 0.05 ng/mL)	Days 0, 7, 14, 21, and 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Anti-drug Antibodies (ADA) to MEDI-528	Number of participants who had ADA detected at each time point	Days 14, 28, 42, and 84
Time to Observed Maximum Serum Concentration (Tmax)	Tmax of MEDI-528	Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Observed Maximum Serum Concentration (Cmax)	Cmax of MEDI-528	Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]	AUC(0-t) of MEDI-528	Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]	AUC(0-infinity) of MEDI-528	Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]	AUC(ext) of MEDI-528	Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Total Body Clearance (CL)	CL of MEDI-528	Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Half-life (T1/2)	T1/2 of MEDI-528	Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84
Terminal Phase Elimination Rate (Vz)	Vz of MEDI-528	Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84

Collaborators and Investigators

• Sponsor: MedImmune LLC
• Investigators: Principal Investigator: Ramon Vargas, MD

Publications and helpful links

General Publications

• White B, Leon F, White W, Robbie G. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther. 2009 Apr;31(4):728-40. doi: 10.1016/j.clinthera.2009.04.019.

Study record dates

Study Major Dates

• Study Start: August 1, 2004
• Primary Completion (Actual): February 1, 2005
• Study Completion (Actual): March 1, 2005

Study Registration Dates

• First Submitted: September 12, 2005
• First Submitted That Met QC Criteria: September 12, 2005
• First Posted (Estimate): September 19, 2005

Study Record Updates

• Last Update Posted (Estimate): March 6, 2014
• Last Update Submitted That Met QC Criteria: February 4, 2014
• Last Verified: February 1, 2014

More Information

Terms related to this study

• Other Study ID Numbers: MI-CP105